FI885031A - Vaextregulator av blodplaettetyp. - Google Patents

Vaextregulator av blodplaettetyp. Download PDF

Info

Publication number
FI885031A
FI885031A FI885031A FI885031A FI885031A FI 885031 A FI885031 A FI 885031A FI 885031 A FI885031 A FI 885031A FI 885031 A FI885031 A FI 885031A FI 885031 A FI885031 A FI 885031A
Authority
FI
Finland
Prior art keywords
vaextregulator
blodplaettetyp
polypeptide
src
induce
Prior art date
Application number
FI885031A
Other languages
English (en)
Other versions
FI100336B (fi
FI885031A0 (fi
Inventor
Daniel R Twardzik
George J Todaro
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen filed Critical Oncogen
Publication of FI885031A0 publication Critical patent/FI885031A0/fi
Publication of FI885031A publication Critical patent/FI885031A/fi
Application granted granted Critical
Publication of FI100336B publication Critical patent/FI100336B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/73—Expression systems using phage (lambda) regulatory sequences
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI885031A 1987-03-02 1988-11-01 Ilmentämiskasetti, menetelmä ja isäntäsolu fuusioproteiinin valmistami seksi FI100336B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US2060987A 1987-03-02 1987-03-02
US2060987 1987-03-02
US11513987A 1987-10-30 1987-10-30
US11513987 1987-10-30
PCT/US1988/000634 WO1988006628A1 (en) 1987-03-02 1988-02-26 Platelet related growth regulator
US8800634 1988-02-26

Publications (3)

Publication Number Publication Date
FI885031A0 FI885031A0 (fi) 1988-11-01
FI885031A true FI885031A (fi) 1988-11-01
FI100336B FI100336B (fi) 1997-11-14

Family

ID=26693642

Family Applications (1)

Application Number Title Priority Date Filing Date
FI885031A FI100336B (fi) 1987-03-02 1988-11-01 Ilmentämiskasetti, menetelmä ja isäntäsolu fuusioproteiinin valmistami seksi

Country Status (14)

Country Link
EP (1) EP0281363B1 (fi)
JP (1) JPH01503513A (fi)
KR (1) KR890700672A (fi)
AT (1) ATE123061T1 (fi)
AU (1) AU623589B2 (fi)
DE (1) DE3853842T2 (fi)
ES (1) ES2074049T3 (fi)
FI (1) FI100336B (fi)
GR (1) GR3017041T3 (fi)
IE (1) IE69678B1 (fi)
IL (1) IL85613A (fi)
NZ (1) NZ223696A (fi)
PT (1) PT86885B (fi)
WO (1) WO1988006628A1 (fi)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4844895A (en) * 1985-11-01 1989-07-04 New York University Composition containing a peptide fragment of platelet factor four and method for restoring suppressed immune responses
US5026639A (en) * 1988-01-14 1991-06-25 Nippon Mining Company, Limited Method to improve mRNA translation and use thereof for production of platelet factor-4
GB2214508A (en) * 1988-01-27 1989-09-06 Bayer Ag Plasmid vector for the efficient expression of foreign genes fused with newly conceived transcriptional and translational signal sequences.
US5800820A (en) * 1989-01-10 1998-09-01 Repligen Corporation Methods and compositions for treatment of angiogenic diseases
US5086164A (en) * 1989-01-10 1992-02-04 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
US5187075A (en) * 1989-01-26 1993-02-16 Sri International Cloning and expression of a variant gene of platelet factor 4 and compositions thereof to modulate immune responses
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
EP0594749A1 (en) * 1991-07-15 1994-05-04 Repligen Corporation Modified pf4 compositions and methods of use
JPH06506702A (ja) * 1992-01-16 1994-07-28 レプリゲン　コーポレーション 脈管形成性の病気の処置用の新規な方法と組成物
WO1995012414A1 (en) * 1993-11-05 1995-05-11 Repligen Corporation Novel modified pf4 compositions and methods of use
CA2148301A1 (en) * 1994-05-09 1995-11-10 Rama Belagaje Expression of recombinant mpf-4, cpf-4, pf-4 and precursor compounds
US5985543A (en) * 1996-10-11 1999-11-16 The Trustees Of The University Of Pennsylvania Compositions and methods for detection of antibody binding to cells
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
WO2007053952A1 (en) * 2005-11-10 2007-05-18 Chemokine Therapeutics Corporation Platelet factor-4 (pf-4) analogs and their use
EP1368483B1 (en) 2001-03-09 2012-10-24 Genentech, Inc. Process for production of polypeptides
US8609621B2 (en) 2010-11-15 2013-12-17 E I Du Pont De Nemours And Company Acid-cleavable linkers exhibiting altered rates of acid hydrolysis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4565785A (en) * 1978-06-08 1986-01-21 The President And Fellows Of Harvard College Recombinant DNA molecule
IL60184A (en) * 1979-05-31 1984-05-31 Schering Ag Process for the specific cleavage of protein sequences from proteins
US4530901A (en) * 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4582800A (en) * 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
SE8300693L (sv) * 1983-02-09 1984-08-10 Sven Lofdahl Sett att framstella och isolera proteiner och polypeptider samt en hybridvektor for detta
EP0133123A1 (en) * 1983-07-25 1985-02-13 Mgi Pharma, Inc. Immunogens of papilloma viruses
US4645828A (en) * 1984-03-23 1987-02-24 Oncogen Platelet related growth regulator
AU4866485A (en) * 1984-09-18 1986-04-08 Sagami Chemical Research Center Cyclic double-stranded dna, process for its preparation, microorganism containing said cyclic double-stranded dna, andprocess for preparing protein containing antigen determinant
JPH0816063B2 (ja) * 1985-03-15 1996-02-21 オンコゲン 腫瘍細胞増殖阻害剤
EP0196864A3 (en) * 1985-03-25 1988-03-23 Cetus Corporation Alkaline phosphatase-mediated processing and secretion of recombinant proteins, dna sequences for use therein and cells transformed using such sequences
JPS61280292A (ja) * 1985-06-04 1986-12-10 Wakunaga Pharmaceut Co Ltd 菌体外分泌による蛋白質の製造法

Also Published As

Publication number Publication date
AU1492488A (en) 1988-09-26
DE3853842T2 (de) 1995-12-07
IE69678B1 (en) 1996-10-02
IE880591L (en) 1988-09-02
EP0281363B1 (en) 1995-05-24
FI100336B (fi) 1997-11-14
IL85613A0 (en) 1988-08-31
EP0281363A3 (en) 1988-11-17
GR3017041T3 (en) 1995-11-30
FI885031A0 (fi) 1988-11-01
ES2074049T3 (es) 1995-09-01
PT86885B (pt) 1995-08-09
ATE123061T1 (de) 1995-06-15
PT86885A (pt) 1989-03-30
DE3853842D1 (de) 1995-06-29
JPH01503513A (ja) 1989-11-30
IL85613A (en) 1994-10-07
NZ223696A (en) 1991-06-25
WO1988006628A1 (en) 1988-09-07
AU623589B2 (en) 1992-05-21
KR890700672A (ko) 1989-04-26
EP0281363A2 (en) 1988-09-07

Similar Documents

Publication Publication Date Title
DK540685D0 (da) Blodpladepeptidbeslaegtet vaekstregulator
FI885031A0 (fi) Vaextregulator av blodplaettetyp.
DE3789320D1 (de) Verabreichungsinstrument zum Einführen von festen Medikamenten.
ZA896468B (en) Lyophilization of red blood cells
DE3888642D1 (de) Rollflasche zur Züchtung von Zellengewebekulturen.
NO820090L (no) Fremgangsmaate for fremstilling og behandling av renninderivater
PH22461A (en) Preparation of functional human urokinase protein
DE3674906D1 (de) Selbstklemmende medizinische prothese und ihre herstellung.
NO164991C (no) Fremgangsmaate for fremstilling av blodkoaguleringshemmende proteiner.
NO880268D0 (no) Fremgangsmaate for fremstilling av anti-koagulerende peptider.
DE3268915D1 (en) Angiotropins of leukocytes and inflamed tissue: a new class of natural chemotropic protein mitogens for specific induction of directional growth of blood vessels, neovascularization of tissues and morphogenesis of blood vessel patterns, process for their biotechnical preparation and pharmaceutical compositions
NO884995L (no) 2',3'-dideoksy-2'-fluornukleosider, fremstilling derav samt preparater inneholdende disse.
DK87190A (da) Fremgangsmaade til at regulere plantevaekst under anvendelse af svovlholdige organiske syrer
DK410887A (da) Protein isoleret fra pattedyrhjernevaev
DE3781483D1 (de) Pharmazeutische zusammensetzung zum schutz von gehirnzellen.
IT1223416B (it) Procedimento per la realizzazione di calzature del tipo ciabatta, nonche' ciabatta cosi' realizzata
EP0136093A3 (en) Anti-cancer factors
AU2715288A (en) Human respiratory syncytialvirus vaccine derived from the 1a (9.5 kd) protein
AU6592890A (en) Treatment of multi-drug resistant tumors with quinolyloxazole-2-ones
IT8621034A1 (it) Perfezionamenti nei procedimenti di preparazione di pelle scamosciata sintetica
EP0331743A4 (en) PROTEIN DERIVED FROM A LIVING BODY.
NO170545C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme 6,21-dimethyl-19-nor-pregna-diener
NO158020C (no) Fremgangsmaate for fremstilling av optisk rent s-3-morfolino-4-(3'-tertbutylamino-2'-hydroxypropoxy)-1,2,5-thiadiazol
TR22570A (tr) Derinin seri olarak tabaklan masina mahsus usul
FI893001A (fi) Foerfarande foer framstaellning av nya, terapeutiskt anvaendbara 1,2-bensisoxazol-3-yl- och 1,2-bensisotiazol -3-ylderivat.

Legal Events

Date Code Title Description
MM Patent lapsed

Owner name: ONCOGEN, A LIMITED PARTNERSHIP